Neutralizing the activity of these molecules might be helpful in the treatment of inflammation associated with RA, as well as with other chronic inflammatory and autoimmune diseases where S100A9 and calprotectin are oversecreted. This evidence concerns the gene S100A9 and rheumatoid arthritis.